digoxin

(redirected from Antiarrhythmic drugs)
Also found in: Dictionary, Thesaurus, Medical.

digoxin:

see digitalisdigitalis
, any of several chemically similar drugs used primarily to increase the force and rate of heart contractions, especially in damaged heart muscle. The effects of the drug were known as early as 1500 B.C.
..... Click the link for more information.
.

digoxin

[dī′gäk·sən]
(organic chemistry)
C41H64O14 A crystalline steroid obtained from a foxglove leaf (Digitalis lanata); similar to digitalis in pharmacological effects.
References in periodicals archive ?
The results from a 10-year randomized trial known as the CABANA trial (Catheter Ablation versus Antiarrhythmic Drug trial for Atrial Fibrillation) have recently been released.
No cardiac injury was determined, and the rhythm reverted to normal sinus rhythm spontaneously on the 3rd hour after the accident without the use of any antiarrhythmic drug.
Findings during electrophysiology testing Finding Atrial flutter Sinus rhythm P value group (n = 94) group (n = 94) Spontaneous atrial 2 (2.1%) 4 (4.3%) 0.68 fibrillation Inducible atrial 7 (7.5%) 20 (21.3%) 0.007 fibrillation Atrial fibrillation 5 (71.4%) 8 (40%) 0.15 requiring cardioversion Median flutter cycle 258 (180-370) 252.5 (183-370) 0.34 length (range), ms Bidirectional block 93 (98.9%) 94 (100%) NA Isthmus dependent 85 (95.5%) 63 (90%) 0.29 Antiarrhythmic drugs 20 (21.3%) 15 (15.9%) 0.35 prescribed at discharge
Propafenone (Rythmol, Abbott, Chicago, IL, USA) is a group 1C antiarrhythmic drug that has sodium channel-blocking effects.
Multiple clinical trials have established the superiority of CA over antiarrhythmic drug therapy (AAD) for the maintenance of sinus rhythm and improvement of quality of life.
Treatment options for arrhythmic syncope include implantable cardiac pacemakers, defibrillators, antiarrhythmic drugs and catheter ablation.
Brugada syndrome is diagnosed in patients with Type 2 or Type 3 ST-segment elevation in [greater than or equal to]1 lead among the right precordial leads V1,V2 positioned in the 2nd, 3rd, or 4th intercostal space when a provocative drug test with intravenous administration of Class I antiarrhythmic drugs induces a Type 1 EKG morphology.
We then summarized the recent advances on the pharmacological effects of natural antiarrhythmic drugs in treating cardiac arrhythmia, exploring their potential mechanisms, and looking for novel targets.